Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Harvard Business School
Colorcon
AstraZeneca
Express Scripts

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR MAXIPIME


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Maxipime

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00609375 ↗ Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen Completed Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia Phase 4 2006-09-01 To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗ Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen Completed Clinica Palermo, Bogota Phase 4 2006-09-01 To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
NCT00609375 ↗ Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen Completed Fundación San Carlos, Bogota Phase 4 2006-09-01 To determine the efficacy of the administration of 7 to 14 days of cefepime in a continuous infusion vs an intermittent (every 8 hours) administration, in adult patients hospitalized in Bogotá with sepsis and bacteremia caused by gram negative bacilli. The outcome was the rate of clinical cure and microbiological cure after 7 and 14 days of initiation of therapy and rates of relapse after 28 days. Hypothesis: The administration of beta lactams in continuous infusion allows a clinical or microbiological cure greater than the intermittent administration.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Maxipime

Condition Name

Condition Name for Maxipime
Intervention Trials
Febrile Neutropenia 1
Myelodysplastic/Myeloproliferative Neoplasms 1
Adult Acute Lymphoblastic Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Maxipime
Intervention Trials
Communicable Diseases 2
Febrile Neutropenia 2
Urinary Tract Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Maxipime

Trials by Country

Trials by Country for Maxipime
Location Trials
Colombia 3
Russian Federation 2
United States 2
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Maxipime
Location Trials
Texas 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Maxipime

Clinical Trial Phase

Clinical Trial Phase for Maxipime
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Maxipime
Clinical Trial Phase Trials
Terminated 2
Completed 2
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Maxipime

Sponsor Name

Sponsor Name for Maxipime
Sponsor Trials
Asociacion Colombiana de Infectologia, ACIN. Infectious Diseases Society of Colombia 1
Forest Laboratories 1
Clinica Palermo, Bogota 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Maxipime
Sponsor Trials
Other 14
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.